Loracarbef (LY 163892) vs amoxicillin/clavulanate in bacterial maxillary sinusitis

Autor:	T A, Sydnor, W M, Scheld, J, Gwaltney, R W, Nielsen, W, Huck, D G, Therasse
Rok vydání:	1992
Předmět:	Adult Male Adolescent Decision Trees Amoxicillin Bacterial Infections Middle Aged Amoxicillin-Potassium Clavulanate Combination Maxillary Sinusitis Severity of Illness Index Cephalosporins Clavulanic Acids Humans Drug Therapy Combination Female Aged
Zdroj:	Ear, nose,throat journal. 71(5)
ISSN:	0145-5613
Popis:	Loracarbef (LY 163892), a beta-lactam antibiotic (carbacephem), was compared with amoxicillin/clavulanate potassium in a 10-day, single-blind, randomized parallel trial in the treatment of acute bacterial maxillary sinusitis. Based on posttherapy aspirate and culture, there was a 95.2% bacteriologic cure rate in patients receiving loracarbef (400 mg twice daily) and an 86.7% cure rate in patients receiving amoxicillin/clavulanate (500/125 mg three times daily) (p = 0.359). Loracarbef was comparable in efficacy to amoxicillin/clavulanate with a more desirable safety profile.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::8e236e7fec9175addbdd40c1b565351b https://pubmed.ncbi.nlm.nih.gov/1505371 Zobrazit plný text záznamu